Clinical trial · no report yet · Phase 3
NCT04793958
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
- NCT04793958 ↗
- Active not recruiting
- Mirati Therapeutics Inc.
- 39 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 14 | |
| Podcasts | 13 | |
| YouTube | 12 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Advanced Colorectal Cancer; Metastatic Colorectal Cancer
- Interventions
- MRTX849; Cetuximab; mFOLFOX6 Regimen; FOLFIRI Regimen
- Arms
- MRTX849 + Cetuximab · Experimental
- mFOLFOX6 or FOLFIRI · Active comparator
- Enrollment
- 461
- Primary outcomes
- Overall Survival (OS)
- Progression-free Survival (PFS)
- Sponsor
- Mirati Therapeutics Inc.
- Start
- Jun 24, 2021
- Primary completion
- Jan 16, 2026
- Results posted
- No
- Registry record
- NCT04793958 · updated Sep 28, 2026
Publications
linked from the registry- Deming DA. Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer. J Natl Compr Canc Netw. 2025 Jan 3;23(1):e247067. doi: 10.6004/jnccn.2024.7067. PubMed 39752885